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ABSTRACT 
Objective : Oestrogen-hypothesis in schizophrenia is a largely debated issue. Being 
a multifactor disorder, schizophrenia has gained importance in the field of psychiatric 
research, especially to dig out the tentative aetiologies (genetic, biological, 
environmental etc.), still under tested or not tested. The present article is an 
attempt only to understand the possible role of oestrogen as a 'core' biological 
factor at the backdrop of male-female differences (in the onset, course, treatment 
response, prognosis) in schizophrenia barring other factors. This is to reduce the 
level of 'conflict' and 'confusion' in the article. 
Method : Electronic data search is the mainstay of the literature bank, included in 
the article and only 'supportive' evidences (direct and indirect) are incorporated to 
understand the role of oestrogen in the brain at the backdrop of schizophrenia. 
Result: The study comes out with a postulation that oestrogen has got a potential 
effect in moderating the process of schizophrenia in the females. 
Conclusion : Oestrogen could be tested as the 'novel' therapeutic agent in the 
female schizophrenics with the necessary support from the modern Nuclear Imaging 
Techniques to get maximum therapeutic benefit in schizophrenia. 
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INTRODUCTION 
'Sex bias' in schizophrenia is an ever 
interesting and well-nurtured topic, because 
it imparts a significant effect in the hetero-
geneirv of schizophrenic population. Amidst 
so many controversies, the 'bias' stands on 
the basis of the observation that males 
usually develop the illness early (Chaves et 
al, 1993), sustain a more vulnerable course 
and often suffer from poorer prognosis than 
females (Meyer er al, 1993). On the other 
hand, females manifest the illness during 
their lifetime when the serum oestrogen 
level is low, for e.g. at the particular phase 
of menstrual cycle (Riecher-Rossler et al, 
1994), after the childbirth (Davies et al, 
1995) and after menopause (Hafner er al, 
1993). 
Among much possible aetiology in schizo-
phrenia, it has been seen that birth-related 
complications lead to the development of 
schizophrenia in the susceptible babies 
(Chattopadhyay & Mandal, 2001). Now, the 
question comes, despite of equal vulnerabil-
ity of development of schizophrenia in 
both the sexes at birth, why male babies 
show such preponderance? To answer the 
question, the present article is focused on 
the tentative roles of oestrogen, a potent 
pleiotropic hormone, responsible for the so-
called "feminity"-a principal biological 
discriminator between two sexes. Other 
possible aetiological components (genetic, 
anatomical variations, environmental factors, 
stress etc.) are excluded from this article to 
concentrate only on the tentative role of 
oestrogen behind the sex-related-heteroge-
ocity in schizophrenia. 
METHOD 
Electronic data search through PubMed 
Entrez for reviewing the available and rel-
evant literature of last two decades with the 
special reference of the updated concepts 
and current studies on oestrogen in schizo-
phrenia. Among the studies, only the sup-
portive evidences (empirical and review) 
have been included in the present paper to 
understand the function of oestrogen at the 
backdrop of schizophrenia' for getting a 
maximally focused view on it. 
RESULT 
The literature search finds that oestrogen 
has gained tremendous significance in die 
field of biomolecular research because of 
its pleiotropic nature. It manipulates the 
pathophysiology of several diseases includ-
ing psychiatric illnesses probably through its 
nuclear receptor gene expression (oestrogen 
has got a nuclear receptor). 
Genetic modeling of oestrogen-metabo-
lism shows that oesrrogen is responsible for 
manipulation of diseases like breast, ovarian 
and colorectal cancers, PCOD (Polycystic 
ovarian Disease), Parkinson's disease, alco-
holism and schizophrenia (Huber et al, 
2002). Further, psychobiological implica-
tions of oestrogen withdrawal in Postmeno-
pausal syndrome are well-known facts. 
Impact of oestrogen on the psychobiology 
of females has direcily been supported by 
the fact that oetrogen-therapy combats the 
adverse psychological symptoms in the 
postmenopausal females (Ozsoy et al 2002) 
Apart from that, oestrogen (transdermal) 
also has been found to be beneficial to liting 
down the psychiatric symptoms of puer-
peral psychosis (Gregoire et al, 1996), an 
encouraging impact on the symptoms of 
schizophrenic females (Kulkari et al, 2002), 
alleviating PCOD related psychological dis-
orders (Kopala et al, 1997) and the premen-
strual tension (Tiemsrra & Patel, 1998). 
Recent studies have showed that oestrogen 
replacement therapy' improves the mood, 
memory and mental status in schizophrenic 
females at a large (lindamer et al, 1997) 
mostly in conjunction with antipsychotics 
(Kulkari et al, 2001; Gregoriadis & Seeman, 
2002), though effects may van- from indi-
vidual to individual (Liao et al, 2002). 
Gregoriadis & Seeman, (2002) also observed 
that oestrogen supplementation along with 
the antipsychotics prevent the occurrence ot 
tardive dyskinesia, a very common side 
effect of antipsychotic medication. 
(205) IS OESTROGEN A-BIOLOGICAL NEUROLEPTIC! 
Level of serum oestrogen has got a 
strong correlation with the cognitive func-
tion especially global cognition, verbal, spatial 
decelaration memory and perceptual motor 
speed and higher oestrogen levels in female 
schizophrenics are associated with the better 
cognitive ability (Hoff et al, 2001). While 
evaluating the molecular process of such 
"oestrogenic effect" in the brain, Garcia-
Segura et al, (2001) found that oestrogen 
prevents several neurodegenerative processes 
by virtue of its nuclear receptor mediated-
alteration of oestrogen-responsive-gene-
expression that modulates the rate of 
apoptosis, axonal degeneration and a gen-
eralized support to the neurons. 
Now, if oestrogen has got modifying 
effect on the neuropsychiatric process in 
females then how it acts in the brain, 
especially in schizophrenia? The answer of 
it probably lies on the fact that oestrogen 
must have some modulating role on 
dopamine and serotonin receptors in the 
relevant part of the brain, affected in 
schizophrenia, as excessive dopamine and 
serotonin, discharges in the mesocortex and 
mesolimbic areas are one of the established 
parthophysiology behind the onset of schizo-
phrenia (Carpenter & Buchanan, 1995). in 
support to the postulation, following animal 
studies have been reviewed to understand 
the biomolecular mechanisms of ocitro-
genie action in the brain. 
Using animal models, studies of Gattaz 
er al. (1992) and Bosse & Di Paolo, (1996) 
showed that oestrogen is a potent dopamine 
receptor blocker, especially D, and D2. A 
series of studies of Fink et al. (1996), Fink 
et al. (1998), Summer and Fink, (1998), Fink 
et al. (1999), Osterlund et al. (2000) docu-
mented that oestrogen can also block se-
rotonin receptors too, especially 5HT|A and 
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CONCLUSION 
Therefore, oestrogen, by blocking the 
dopamine and serotonin receptors in the 
brain probably serves alike neuroleptics, 
which are either purely dopamine blockers 
(chlorpromazine, haloperidol, clozapine etc.) 
or dopamine plus serotonin blockers 
(Risperidone). Therefore, it could be postu-
lated that oestrogen, by blocking the 
dopamine and serotonin receptors in the 
brain probably serves like neuroleptics in 
females (due to its natural abundance). 
Given such documentarions it seems that 
oestrogen could be a natural psycho 
protectant in femalesl and it needs to be 
tested further. 
Strategy for the future research to re-
evaluate the effect of oestrogen on schizo-
phrenia could be: 
A. Clinical trial 
First episode female schizophrenics may 
be tried with oral or transdermal oestrogen 
(available standard daily dose) alone for a 
particular period of time (may be for first 
three cycles or even beyond that according 
to dose-response graph) and symptom-
variation could be noted using BPRS (Brief 
Psychiatric Ratting Scale) and Hamilton's 
Rating Scale For Depression (HAM-D). 
Patients who do not respond may be added 
antipsychotic medication its the lowest 
possible dosage and the symptoms are rated 
using Nurse's Observation Scale. 'Observa-
tions' and 'ratings' of the changes in the 
symptoms including the adverse effects of 
the drugs used should be marched with the 
serial estimation of serum oestradiol (the 
most potent among the biologically available 
oestrogen to titrate the most effective dosage 
of oesrrogen or oestrogen plus 
antipsychotics. 
B. Utilization of Nuclear Imaging 
Techniques 
Nuclear Imaging Techniques like PET 
(Positron Emission Tomography), SPECT 
(Single Photon Emission Computed Tom-
ography.) or fMRI (Functional Magnetic 
Resonance Imaging) could be the useful 
adjunct to suds clinical study by providing 
(i) the rate of receptor occupancy (dopamine 
and serotonin in the relevant areas in the 
brain) by oestrogen could be tallied with the 
syospromatic improvement, especially the 
maximum and the plasma oestrogen level 
at that time, ii) delineation of the change 
of metabolism of those parts, possibly 
affected by oestrogen, matched with the 
possible therapeutic benefit, and III) 
measurement of most effective dosage of 
oestrogen in the treatment of (A schizo-
phrenia. 
REFERENCES 
Chaves AC, Seman MV.Man jj,A MalufA.(I993). 
Schizophrenia: impact of positive symptoms on 
gender social role. Schizophrenia Research, 11, 
41-45. 
Meyer C, Kerterborn G, & Naber D. (1993). Age 
of onset in schizophrenia: relations to 
psychopathology and gender. British journal of 
Psychiatry, 162, 66S-67I. 
Riecher-Rossler A, Hafher H, Stumbaum M, 
Maurer K, & Schmidt R. (1994). Can estradiol 
modulate schizophrenic symptomarology? Schizo-
phrenia Bulletin, 20, 203.214. 
Davies A, Mclvor Rj, & Kumar RC. (1995). 
Impact of childbirth on a series of schizophrenic 
mothers: a comment on the possible influence 
of oestrogen on schizophrenia. Schizophrenia 
Research, 16, 25-31. 
Hafher H, et al (1993).A chapter In systematic 
schizophrenia research-the search for causal 
explanations for sex differences in age of 
onset.Nervenarzt 64, 706-716. 
ChattDpadhyayS,MandalMK- Schizophrenia and 
Obstetrical Complications Are they related? In: 
Mandal MKi Haque-Nizamie S editors- Current 
developments in schizophrenia. 1st edition. New 
Delhi: Allied Publishers, 2001. (Accepted for 
publication). 
Huber JC, Schneeberger C,Tempfer CB. (2002). 
Genetic modelling of the estrogen metabolism 
as a risk factor of hormonedependentdisorders. 
Maturitas 42 (I): 1-12. 
Ozsoy M, Oral B, & Ozsoy D. (2002). Clinical 
equivalence of intranasal estradiol and oral 
estrogens for postmenopausal symptoms. Inter-
national Journal of Gynecology & Obstetrics, 
79(2), 143-146. 
Gregoire Aj, Kumar R, Everitt B, Henderson AF, 
& Studd jW. (I 996).Transdermal aestrogen for 
treatment of severe postnatal depression. Lancet 
347. 930-33. 
KuMcami J, et al (2002). Clinical trial of adjunctive 
oestrogen treatment in women with schizophrenia. 
Archives of Women's Mental Health 5(3): 99-
104. 
Kopah IC.Lewine R,Good KP.Furker r^MartdaB 
jS, & Hones WG. (1997). Clinical features of 
schizophrenis in woman with hyperandrogenism. 
Journal of Psychiatry & Neuroscienee, 22, 56-
60. 
TiemstraJD A PateJ K.(I998).Hormonal therapy 
in the management of premenstrual syndrome. 
Journal of American Board of Family Practice, 
H(S), 378-81. 
Carpenter WT A Buchanan R.N. (1995). 
(206) CHATTOfttDHW 
Schizophrenia: introduction and overview in HI. 
Kaplan & Bl. Sadock (eds.), Comprehensive 
Textbook of PsychiatryNI. Baltimore: Williams 
and Wilkins. 
Gattaz, WR, Behrens, S., Dc Vry, J. ft Hafher, 
H. (1992). [Estradiol inhibits dopamine mediated 
behavior in rats-as an animal model of sex-
specific differences in schizophrenia.] Fortschritte 
der Neurologie Psychiatric, 60, 8-16. 
Botse R & DiPaolo T. (1996). The modulation 
of brain dopamine and GABA A receptors by 
estradiol: a clue for CNS changes occurring at 
menopause. Cell, Molecule & Neurobiology 16, 
199-2 12. 
Fink, G., Summer, B.E., Rosie, R., Grace, O., ft 
Quinn, j.R (1996). Estrogen control of central 
neurotransmission: effect on mood, mental state, 
and memory. Cell, Molecule & Neurobiology Id, 
325-344. 
Fink, G., Summer, B.E., McQueen, j.K., Wilson, 
H., ft Rosie, R. (1998). Sex steroid control of 
mood, mental state and memory. Clinical & 
Experimental Pharmacology & Physiology 25, 
764-775. 
Summer BE ft Fink G. (1998).Testosterone as 
well as estrogen increases serotonin 2A receptor 
mRNA and binding site densities in the male rat 
brain. Brain Research & Molecular Brain Research, 
59, 205-214. 
Fink et al (1999). Androgen action on central 
serotonin neurotranamission : relevance for mood, 
mental state and memory. Behavior & Brain 
Research, 105. 53-68. 
Osteriund M K, Halldin C, ft Hurd Y (2000). 
Effects of chronic I 7-beta-estradiol treatment on 
the serotonin S-HT (IA) receptor RNA and 
binding level in the rat brain. Synopsis, 35. 39-
44. 
Undamer LA, Lohr jB, Hans MJ, & jeste DV. 
(1997). Gender, oestrogen, and schizophrenia. 
Psychopharmacological Bulletin, 33, 221-228. 
Kulkarni et al .(2001). Estrogen - a potential 
treatment for schizophrenia. Schizophrenia 
Research. 48(1), 137-44. 
Gregoriadis S ft Seeman MV. (2002).The role 
of estrogen in schizophrenia: implications for 
schizophrenia practice guidelines for women. 
Canadian journal of Psychiatry 47(S), 437- 42. 
Hoff et al (2001).Association of oestrogen levels 
with neuropsychological performance in women 
with schizophrenia. American lournal of Psychiatry 
158, 1134-9. 
Uao D, Chen H, Lee S, ftTsai S. (2002). Estrogen 
supplementation for female schizophrenics treated 
with atypical antipsychotics. General Hospital 
Psychiatry 24(5), 357. 
Garcia-Segura LM, Azcoitia I, DonCarlos LI. 
2001 . Neuro rotection by estradiol. Progressive 
Neurobiology, 63(1). 29-60. 
* SUBHAGATA CHATTOPADHYAY. B-166, IIT Kharagpur, Kharagpur- 721 302, West Bengal. Tel. No: (03222)- 277054 ®, 282651®, and 2826S0 (O). 
E-mail : subhagatachatteriee@yahoo.com 
(207) 